01 1分钱废标后，还是1分钱中标 导读： 医疗仪器设备低价采购屡禁不止反而日渐"猖狂"、愈演愈烈，怎么办？谁之过？ 日前，一则全自动生化免疫流水线检测仪中标信息被中国政府采购网公开，该标的中标过程可 谓 一波三折 ，可结果却是令人唏嘘讶异。 11月17日， 中国政府采购网发布了《漳州市卫生健康委员会（漳州市医用设备集中采购工作 小组办公室）全自动生化免疫流水线检测仪等医疗设备统招分签采购项目(三次)结果公告（采 购包1）》。 公告显示， 迈瑞 自动血细胞分析仪流水线成功中标， 成交金额为0.01元 ，供应商为漳州片 仔癀医疗器械有限公司。 | 国政府示财政 | EIXUNSTIES E TTH | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | WWW.CCQD.QOV.CO | | | | | | | | | | | | | | | 监督检查 | 国际专栏 | 前页 | 购买服务 | 信息公告 | 政来法规 | | | | | | ...

Core Viewpoint - The Ministry of Finance has issued a notice to address the issue of abnormally low bids in government procurement, marking a significant shift from a focus on low prices to an emphasis on quality and effectiveness in the medical equipment market [4][7]. Group 1: Government Procurement Reforms - The new regulations aim to combat the persistent issue of low-price bidding in the medical equipment sector, which has been detrimental to product quality and patient safety [9][10]. - The notice introduces a closed-loop system focusing on "source control, process review, and post-responsibility," addressing previous challenges in identifying and managing low-price bids [10][12]. Group 2: Impact on Medical Equipment Market - The introduction of a full lifecycle cost concept in procurement will require consideration of ongoing maintenance and consumable costs, thereby preventing the common practice of low initial bids followed by high consumable prices [12][13]. - The new rules will enhance scrutiny of low-price bids, with specific criteria established to identify and reject bids that are excessively low compared to market averages [12][13]. Group 3: Industry Dynamics and Competition - The reforms are expected to shift the competitive landscape, pushing domestic companies to transition from a price-based strategy to one focused on value [14]. - Foreign brands may benefit from the new emphasis on quality and service, as their technological advantages can be better recognized under the new evaluation criteria [14][15]. Group 4: Innovation and Market Growth - The reduction of low-price competition is anticipated to lead to increased investment in research and development, fostering innovation within the industry [15]. - With a projected budget of 19.6 billion for medical equipment updates, the new policies are expected to direct funds towards high-quality products and services, enhancing the efficiency of public healthcare resource allocation [15].

Core Viewpoint - The Ministry of Finance has issued a notice to address the issue of abnormally low bids in government procurement, signaling a shift from a focus on low prices to quality and effectiveness in the medical equipment market [1][3]. Government Procurement Reform - The new draft aims to create a systematic governance framework to tackle the persistent issue of low-price bidding in government procurement, particularly in the medical sector [3][5]. - Pilot programs have been initiated in various free trade zones and cities to address the problem of abnormal low-price bids [3]. Abnormal Low-Price Bidding Issues - The medical equipment sector has seen extreme price reductions, with bids often significantly below market rates, raising concerns about quality and safety [4][5]. - Examples include a bid of 1,000 yuan for a 3 million yuan project, highlighting the risks associated with such low bids [4]. Impact on Industry Competition - Abnormal low-price bidding has led to a decline in the quality of medical equipment and services, affecting patient safety and healthcare outcomes [5]. - The competition has forced some manufacturers to shift focus from R&D to lower-end products, hindering the advancement of domestic brands [5]. New Procurement Guidelines - The draft emphasizes a full lifecycle cost approach, requiring that ongoing maintenance and consumable costs be considered in bid evaluations [6]. - It introduces a two-stage evaluation process for complex equipment, ensuring that quality is prioritized over price [6]. Monitoring and Accountability - The draft outlines clear criteria for identifying abnormal low-price bids, aiming to prevent extreme cases from occurring [7]. - Suppliers will be required to provide cost breakdowns, and the evaluation committee will verify prices against market standards [7]. Market Restructuring - The new regulations are expected to shift market dynamics, concentrating resources on high-quality companies and altering the competitive landscape between domestic and foreign brands [8][9]. - Domestic companies must transition from competing on price to emphasizing value, or risk losing market share [9]. Opportunities for Foreign Brands - Foreign brands may benefit from the new focus on quality and lifecycle costs, allowing them to leverage their technological advantages in the market [10][11]. - The policy changes will require foreign companies to adapt their pricing strategies and enhance local services to maximize their market potential [11]. Innovation and Development - The new policies are anticipated to foster innovation within the industry, encouraging companies to invest in R&D and focus on developing innovative medical devices [11]. - With a significant budget for medical equipment updates, the new regulations will direct funds towards high-quality products and services, promoting a transition to high-quality development in the industry [11].